Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Evaluation of a candidate anti-arthritic drug using the mouse collagen antibody induced arthritis model and clinically relevant biomarkers.

Bender AT, Spyvee M, Satoh T, Gershman B, Teceno T, Burgess L, Kumar V, Wu Y, Yang H, Ding Y, Akare S, Chen Q.

Am J Transl Res. 2013;5(1):92-102. Epub 2013 Jan 21.

2.

Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.

Joosten LA, Lubberts E, Helsen MM, Saxne T, Coenen-de Roo CJ, Heinegård D, van den Berg WB.

Arthritis Res. 1999;1(1):81-91. Epub 1999 Oct 26.

3.

In vivo imaging of protease activity in arthritis: a novel approach for monitoring treatment response.

Wunder A, Tung CH, Müller-Ladner U, Weissleder R, Mahmood U.

Arthritis Rheum. 2004 Aug;50(8):2459-65.

4.

T cells are involved in the development of arthritis induced by anti-type II collagen antibody.

Mitamura M, Nakano N, Yonekawa T, Shan L, Kaise T, Kobayashi T, Yamashita K, Kikkawa H, Kinoshita M.

Int Immunopharmacol. 2007 Oct;7(10):1360-8. Epub 2007 Jun 26.

PMID:
17673151
5.
6.

Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis.

Schwager K, Kaspar M, Bootz F, Marcolongo R, Paresce E, Neri D, Trachsel E.

Arthritis Res Ther. 2009;11(5):R142. doi: 10.1186/ar2814. Epub 2009 Sep 25.

7.

Multi-response model for rheumatoid arthritis based on delay differential equations in collagen-induced arthritic mice treated with an anti-GM-CSF antibody.

Koch G, Wagner T, Plater-Zyberk C, Lahu G, Schropp J.

J Pharmacokinet Pharmacodyn. 2012 Feb;39(1):55-65. doi: 10.1007/s10928-011-9230-4. Epub 2011 Dec 23.

PMID:
22193331
8.

Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis.

Plater-Zyberk C, Joosten LA, Helsen MM, Sattonnet-Roche P, Siegfried C, Alouani S, van De Loo FA, Graber P, Aloni S, Cirillo R, Lubberts E, Dinarello CA, van Den Berg WB, Chvatchko Y.

J Clin Invest. 2001 Dec;108(12):1825-32.

9.

CEL-2000: A therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model.

Zimmerman DH, Taylor P, Bendele A, Carambula R, Duzant Y, Lowe V, O'Neill SP, Talor E, Rosenthal KS.

Int Immunopharmacol. 2010 Apr;10(4):412-21. doi: 10.1016/j.intimp.2009.12.016. Epub 2010 Jan 13.

PMID:
20074669
10.
11.

Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.

Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, van den Berg WB.

Arthritis Rheum. 2004 Feb;50(2):650-9.

12.

Inhibitory effects of a traditional Chinese herbal formula TBL-II on type II collagen-induced arthritis in mice.

Shen X, Li C, Zhao H, Li S, Chen J, Kobayashi Y, Shen W.

J Ethnopharmacol. 2011 Mar 24;134(2):399-405. doi: 10.1016/j.jep.2010.12.033. Epub 2011 Jan 5.

PMID:
21215307
13.

A novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models.

Chen Q, Muramoto K, Masaaki N, Ding Y, Yang H, Mackey M, Li W, Inoue Y, Ackermann K, Shirota H, Matsumoto I, Spyvee M, Schiller S, Sumida T, Gusovsky F, Lamphier M.

Br J Pharmacol. 2010 May;160(2):292-310. doi: 10.1111/j.1476-5381.2010.00647.x.

14.

[Recent progress in mycobacteriology].

Okada M, Kobayashi K.

Kekkaku. 2007 Oct;82(10):783-99. Japanese.

PMID:
18018602
15.

The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis.

McCoy JM, Wicks JR, Audoly LP.

J Clin Invest. 2002 Sep;110(5):651-8.

16.

MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis.

Clark P, Rowland SE, Denis D, Mathieu MC, Stocco R, Poirier H, Burch J, Han Y, Audoly L, Therien AG, Xu D.

J Pharmacol Exp Ther. 2008 May;325(2):425-34. doi: 10.1124/jpet.107.134510. Epub 2008 Feb 20.

17.

Suppressive role of leukocyte cell-derived chemotaxin 2 in mouse anti-type II collagen antibody-induced arthritis.

Okumura A, Saito T, Otani I, Kojima K, Yamada Y, Ishida-Okawara A, Nakazato K, Asano M, Kanayama K, Iwakura Y, Suzuki K, Yamagoe S.

Arthritis Rheum. 2008 Feb;58(2):413-21. doi: 10.1002/art.23215.

18.

Blockade of NKG2D ameliorates disease in mice with collagen-induced arthritis: a potential pathogenic role in chronic inflammatory arthritis.

Andersson AK, Sumariwalla PF, McCann FE, Amjadi P, Chang C, McNamee K, Tornehave D, Haase C, Agersø H, Stennicke VW, Ahern D, Ursø B, Trowsdale J, Feldmann M, Brennan FM.

Arthritis Rheum. 2011 Sep;63(9):2617-29. doi: 10.1002/art.30460.

19.

Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis.

Honda T, Segi-Nishida E, Miyachi Y, Narumiya S.

J Exp Med. 2006 Feb 20;203(2):325-35. Epub 2006 Jan 30.

20.

Utility of animal models for identification of potential therapeutics for rheumatoid arthritis.

Hegen M, Keith JC Jr, Collins M, Nickerson-Nutter CL.

Ann Rheum Dis. 2008 Nov;67(11):1505-15. Epub 2007 Nov 29. Review.

PMID:
18055474
Items per page

Supplemental Content

Write to the Help Desk